Sign in

You're signed outSign in or to get full access.

CN

ClearPoint Neuro, Inc. (CLPT)·Q1 2024 Earnings Summary

Executive Summary

  • Record revenue of $7.64M (+41% YoY), driven by 61% growth in Biologics & Drug Delivery and a 255% increase in Capital Equipment & Software; gross margin held at 59% .
  • Eight new hospital customers activated (a quarterly record), expanding global centers to 80+; SmartFrame OR received 510(k) clearance and first clinical cases were performed, setting up OR-driven disposable growth beginning in Q2 .
  • Operational cash burn reduced to $3.8M (-32% YoY); cash and equivalents rose to $35.4M aided by ~$16.2M net equity proceeds .
  • FY 2024 revenue outlook reaffirmed at $28–$32M; management maintained guidance citing non-recurring Q1 capital placements that may normalize, with disposables expected to offset in H2 via SmartFrame OR and PRISM Laser .

What Went Well and What Went Wrong

What Went Well

  • Record quarterly revenue and strong mix: “Overall, the company achieved record revenue of $7.6 million or 41% growth, led by 61% growth in biologics and drug delivery revenue, and 255% growth in capital sales and service” .
  • Commercial footprint expansion: “Our device business activated eight new sites in the quarter… our fastest activation period ever” with over 80 global centers .
  • Strategic product progress: SmartFrame OR clearance and initial cases; multiple PRISM placements and software upgrades; FDA clearance of ancillary bone anchor to enable OR laser fiber placement with third-party navigation/robotics .

What Went Wrong

  • Functional neurosurgery navigation and therapy revenue declined 18% YoY to $1.9M, primarily due to pausing a BCI co-development program (-$0.5M service) .
  • Q1 strength partly non-recurring: management cautioned Q1 capital sales (~$1.4M) are unlikely each quarter, keeping the FY revenue range unchanged despite the strong start .
  • Gross margin flat at 59% YoY; while stable, mix effects (capital, services) limit margin expansion for now .

Financial Results

MetricQ1 2023Q4 2023Q1 2024
Revenue ($USD Millions)$5.433 $6.8 $7.639
Diluted EPS ($)($0.23) N/A($0.16)
Gross Margin (%)59% 59% 59%
Operating Expenses ($USD Millions)$8.9 $8.7 $8.8

Segment revenue breakdown:

Segment ($USD Millions)Q1 2023Q1 2024
Biologics & Drug Delivery$2.7 $4.3
Functional Neurosurgery Navigation & Therapy$2.4 $1.9
Capital Equipment & Software$0.4 $1.4

KPIs and balance/cash flow:

KPIQ1 2023Q1 2024
New hospital customers activated (units)N/A8
Global centers (count)N/A80+
Operational cash burn ($USD Millions)$5.68 $3.84
Cash & Equivalents ($USD Millions)$21.792 $35.353
Net equity proceeds ($USD Millions)—$16.183
Gross margin (%)59% 59%

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueFY 2024$28–$32M $28–$32M Maintained
Operational cash flow breakevenLong-termH2 2025 target Goal reaffirmed (no change in timeline provided) Maintained

Earnings Call Themes & Trends

TopicQ3 2023 (Previous Mentions)Q4 2023 (Previous Quarter)Q1 2024 (Current Period)Trend
Cash discipline & OpExPriority to flatten OpEx; op cash burn Q3 at $1.8M (lowest since 2020) OpEx discipline; cash burn lowest in years; equity raise to retire debt Op cash burn down 32% YoY to $3.8M; cash $35.4M post raise Improving
OR expansion (SmartFrame OR)Submitted SmartFrame OR to FDA FDA clearance expected; limited release planning 510(k) cleared; first clinical cases; disposables expected to ramp from Q2 Accelerating
PRISM Laser TherapyLMR in progress; validation; planning accessories & 1.5T study LMR advancing; OR accessory expected H1’24; 1.5T submission targeted Multiple placements; new software; accessory clearance enabling OR placement Building momentum
Biologics & Drug Delivery55% segment growth; deeper strategic partnerships; GLP readiness planned 76% Q4 segment growth; >50% 2024 revenue from BDD anticipated 61% growth; partner BLA submission (PTC Therapeutics); progressing IDE trials Strong, diversified
Functional neurosurgerySegment decline due to paused BCI services; rental model shift Capex growth expected in 2024; software v2.2 with Maestro -18% YoY; pause in BCI services; expect turnaround via OR & PRISM disposables Near-term mixed
Global expansion & regulatoryNew Carlsbad facility; exiting Irvine; MDR progress First EU MDR product approval; global installs 80+ centers globally; more countries targeted via pharma partners Steady progress

Management Commentary

  • “Our ClearPoint Neuro team enjoyed the best operating performance in our Company’s history… record revenue of $7.6 million or 41% growth” — Joe Burnett, President & CEO .
  • “Our device business activated eight new sites in the quarter… expected to support case volume and disposable revenue growth starting in the second quarter” .
  • “We achieved FDA clearance of a key ancillary bone anchor… facilitate laser applicators being placed… with other common operating room navigation and robotic systems” .
  • “We continue to expect revenue for the year in the range of $28 million to $32 million” .

Q&A Highlights

  • Guidance: Management kept FY 2024 revenue range unchanged, citing non-recurring capital sales in Q1 and expecting disposables to drive H2 growth via SmartFrame OR and PRISM .
  • Site activation drivers: Pharma trial participation needs, comprehensive offering (navigation + laser), and OR expansion enabled the surge in new sites; ramp to disposables expected within 3 months .
  • Customer expansion pattern: New sites often start with DBS navigation, then expand to epilepsy/tumor laser ablation and ultimately cell/gene therapy trials; ClearPoint’s platform workflow is 90–95% common across procedures .
  • Biologics growth: Largely from existing partners maturing programs (repeatability, tox, flow control studies), with added new partners; revenue per program increases as candidates progress .

Estimates Context

  • Wall Street consensus (S&P Global) for Q1 2024 revenue/EPS could not be retrieved due to SPGI daily request limits; comparisons to consensus are unavailable at this time. Values would be retrieved from S&P Global if available.

Key Takeaways for Investors

  • Q1 beat on operational execution: record revenue (+41% YoY), stable GM (59%), improved cash burn (–32% YoY), and a strengthened balance sheet ($35.4M cash) support 2024 investment in disposables and services .
  • Mix shift tailwinds: Expect disposables growth from SmartFrame OR and PRISM Laser in H2 as new sites transition from capital installs to recurring procedural volume .
  • Biologics durability: Continued partner progression (e.g., PTC Therapeutics BLA submission) and expanded preclinical services underpin segment strength and provide diversified exposure across >35 indications .
  • Near-term headwind: Functional neurosurgery segment was pressured by paused BCI service revenue; management anticipates recovery via OR disposable adoption and broader therapy access .
  • Guidance stance prudent: FY 2024 revenue range maintained ($28–$32M) given non-recurring Q1 capex; watch Q2/Q3 for disposables inflection and OR ramp .
  • Strategic catalysts: OR expansion, accessory clearances, software advances (Maestro, Array), and global center growth (>80) set up multi-pillar contribution in 2024 .
  • Balance sheet optionality: Post-raise cash enables flexibility to retire convertible debt in Jan 2025 if needed, lowering risk heading into commercialization phases .

Appendix: Source Notes

  • Q1 2024 8-K press release and financials (Exhibit 99.1), plus balance sheet and cash flows .
  • Q1 2024 earnings call transcript (prepared remarks and Q&A) .
  • Prior quarters: Q4 2023 earnings call for trend and prior guidance . Q3 2023 earnings call for cash/OpEx trajectory and pipeline .
  • Other press releases in the Q1 timeframe: None found within Jan–Mar 2024. Notable early-Q2 releases include SmartFrame OR and PRISM full market release (June 1) and Aspen Neuroscience trial using ClearPoint Navigation (June 20) .